NeoGenomics Acquires Inivata to Access Liquid Biopsy Technology

SOME BELIEVE THAT LIQUID BIOPSY TECHNOLOGY has the potential to develop into a Holy Grail of cancer diagnostics. Yet progress in this field has been slow. Now a recent lab acquisition may accelerate the development of clinically-useful liquid biopsies. There is keen interest in how to achieve the noninvasive diagnosis of cancer. Investors have ploughed …

NeoGenomics Acquires Inivata to Access Liquid Biopsy Technology Read More »

To access this post, you must purchase The Dark Report.

NeoGenomics Acquires Inivata to Access Liquid Biopsy Technology

FDA gave Inivata’s RaDaR technology designation as a ‘breakthrough device’

Comments

TABLE OF CONTENTS

Need A Group Membership? Company Discounts are Available!

You are reading premium content from The Dark Report, your primary resource for running an efficient and profitable laboratory.

Get Unlimited Access to The Dark Report absolutely FREE!

You have read 0 of 1 of your complimentary articles this month

You have read 0 of 1 of your complimentary articles this month